 Follow-up to evaluate the immunogenicity and safety of three production lots of GSK Biologicals MMRV vaccine given as a two-dose schedule to healthy children in their second year of life, as compared to separate administration of GSK Biologicals measles-mumps-rubella MMR vaccine Priorix and varicella vaccine Varilrix in Germany Austria. Blood samples were collected at three time points during the follow-up period Year 1, 2 3. No new subjects will be enrolled in these follow-up phases of the study. 